“Bausch & Lomb’s top priority is the safety of our customers, and we want them to have complete confidence in our products,” said the eye-care product maker’s chief executive, Ronald Zarrella.

“There does appear to be an association between the formulation itself as well as certain use patterns in creating this higher-than-normal incidence of these particular infections,” Dr. Daniel Schultz, director of the FDA’s Center for Devices and Radiological Health, said in a conference call with reporters.